Curis (CRIS) Stock Price Down 5.2%

Shares of Curis, Inc. (NASDAQ:CRIS) dropped 5.2% during trading on Thursday . The company traded as low as $0.55 and last traded at $0.55. Approximately 970,053 shares were traded during trading, a decline of 38% from the average daily volume of 1,552,220 shares. The stock had previously closed at $0.58.

CRIS has been the subject of a number of research analyst reports. Guggenheim began coverage on Curis in a research report on Monday, October 23rd. They set a “buy” rating and a $7.00 price target for the company. Zacks Investment Research lowered Curis from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $6.50.

The firm has a market cap of $90.30, a price-to-earnings ratio of -1.41 and a beta of 1.56. The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15.

In other news, CEO Ali Ph.D. Fattaey acquired 50,000 shares of Curis stock in a transaction on Wednesday, November 15th. The stock was acquired at an average cost of $1.06 per share, with a total value of $53,000.00. Following the completion of the acquisition, the chief executive officer now owns 115,890 shares in the company, valued at $122,843.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.07% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its holdings in Curis by 62,201.8% during the third quarter. JPMorgan Chase & Co. now owns 2,381,798 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 2,377,975 shares during the period. Vanguard Group Inc. grew its holdings in Curis by 2.6% during the second quarter. Vanguard Group Inc. now owns 4,955,068 shares of the biotechnology company’s stock valued at $9,365,000 after purchasing an additional 127,443 shares during the period. State Street Corp grew its holdings in Curis by 10.4% during the second quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock valued at $3,511,000 after purchasing an additional 175,424 shares during the period. First Eagle Investment Management LLC grew its holdings in Curis by 10.4% during the third quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock valued at $39,498,000 after purchasing an additional 2,500,000 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Curis by 1.6% in the second quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 1,880 shares during the period. 55.34% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Curis (CRIS) Stock Price Down 5.2%” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2018/02/08/curis-cris-stock-price-down-5-2.html.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit